Research Projects

IBD National Study Group meeting at the ECCO Congress

Since IBD National Study Groups often come up with solid clinical research questions but face problems with recruiting a decent number of patients, the Clinical Research Committee of ECCO (ClinCom) decided to organise a meeting for representatives of European IBD National Study Groups to meet and to exchange views on study projects. The 1st edition of the IBD National Study Group meeting took place at the ECCO Congress 2016 Amsterdam, with the clear aim to support the collaboration among study groups. Following the successful experience, the IBD National Study Group meeting now takes place on a yearly basis, at the ECCO Congress.

Prior to the meeting, a call for study proposals is sent to the IBD Community, to give investigators the opportunity to present their study projects directly to representatives of IBD National Study Groups, to challenge their ideas and foster interest. Each protocol received goes through a free and thorough assessment in two stages (see details in section “Review of Study Protocol: A Two-Stage Process).

Which kind of studies are presented at the IBD National Study Group meeting?

    • Multicentric studies, executed predominantly in Europe
    • Studies with simple and practical designs, with the goal to recruit a high number of patients
    • Observational, non-interventional and retrospective studies. Randomised clinical trials are not recommended as these studies generally require a highly complex design
    • Studies proposed by independent researchers (investigation must be independent of industry interests)

IBD National Study Group Meeting 2021 – Call for proposals

Review of study protocol: A two-stage process

The assessment of a clinical research protocol encompasses a two-stage process. During the first stage, applicants are called upon to provide a study synopsis including background, design, objectives, outcome parameters, major inclusion and exclusion criteria, statistics, and co-variates not exceeding 4 pages. The first stage’s template is sent by the ECCO Office to the interested submitters upon request, once the call is issued.

Once this first stage application is submitted, the project is reviewed by ClinCom who decides to either support or decline the presentation at the National Study Group Meeting. After the meeting, the PI is invited to submit a full protocol (2nd stage) taking into account the feedback given during the IBD National Study Group meeting. A 2nd stage template is sent by the ECCO Office to the PI.

After the review and approval of the 2nd stage protocol by ClinCom and by the ECCO Governing Board, ECCO offers to support the dissemination of a call to participate to the study project among the IBD Community, to support the recruitment of centres. ECCO does not provide any financial or logistical support to studies. The review by ClinCom of a study protocol is not an ECCO endorsement to the project. It is not allowed to use ECCO’s name and logo to promote a study. ClinCom’s support should be acknowledged in any publication.
Should you have any questions, please contact the ECCO Office (This email address is being protected from spambots. You need JavaScript enabled to view it.)

Open research studies

GlobalSurg | CovidSurg Week 

Project leaders:
NIHR Global Health Research Unit on Global Surgery
Purpose and outcome:
  • To determine the optimal timing of surgery following SARS-CoV-2 infection;
  • Determine assess key global surgical indicators, such as postoperative mortality.
Deadline to participate: October 2020
Target group:
  • In order to achieve the above aims, this study will include all patients undergoing surgery
    with a preoperative, postoperative or no SARS-CoV-2 infection.
  • All hospitals are eligible
    to participate, regardless having admitted SARS-CoV-2 infected patients or not.
Link to the invitation letter

Invitation letter

The Efficacy of Post-Operative Prophylaxis with either vedolizumab or ustekinumab for Crohn's Disease

Project leaders:
IBD center at Rabin Medical Center (Petah-Tikva, Israel)
Purpose and outcome: A multicenter retrospective cohort study to assess the efficacy of either vedolizumab or ustekinumab (cases) compared with anti-TNFs (controls) for the prevention of CD recurrence after a curative ileocecal resection.
Deadline to participate: If you are interested in collaboration to this study, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it. by December 1, 2020.
Target group:
  • Centers which maintain a list of patients treated with biologic treatments and surgery
  • Centers who have the ethical approval for collecting retrospective patient’s data or are willing to get the local ethical committee approval for collecting these retrospective anonymized data 
Results: Submission of an abstract to ECCO'21 and a full manuscript thereafter
Link to the invitation letter

Invitation letter

Closed research studies

Safety and efficacy of combining two biological therapies together or a biological therapy with a new small molecule in patients with IBD and other immune mediated inflammatory diseases 
Project leaders:
Belgian IBD Research and Development group (BIRD)
Purpose and outcome: • To study the efficacy and safety of combining biological treatments together, or with new small molecules in IBD and IMID.
• To identify subgroups of patients who may present safety issues either due to the drugs combinations or patient characteristics  itself (age, comorbidities, previous medical history etc.)
• To study the outcome on extra-intestinal manifestations if any.
• To study the effect of the combination treatment on IBD and IMID disease activity.
Results: Submission of an abstract to ECCO'21 and a full manuscript thereafter
Effectiveness of dose escalation of ustekinumab in Crohn's disease
Project leaders:
Sheba Medical Center (Ramat Gan, Israel)
Purpose and outcome: In patients losing response to ustekinumab, possible therapeutic options may include shortening of interval between doses and intravenous reinduction. However, there is very little evidence to support the effectiveness of dose-optimisation strategy to manage primary or secondary non-response to ustekinumab. Thus, we are proposing a wide collaborative retrospective study to evaluate the effectiveness of dose escalation strategy with usekinumab in CD.


Full manuscript: 

Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy. Kopylov U, Hanzel J, Liefferinckx C, De Marco D, Imperatore N, Plevris N, Baston‐Rey I, Harris RJ, Truyens M, Domislovic V, Vavricka S, Biemans V, Myers S, Sebastian S, Ben‐Horin S, González Lama Y, Gilletta C,  Shitrit Ariella B-G, Zelinkova Z, Weishof R, Storan D, Zittan E, Farkas K, Molnar T, Franchimont D, Cremer A, Afif W, Castiglione F, Lees C, Barreiro‐de Acosta M, Lobaton T, Doherty G, Krznaric Z, Pierik M, Hoentjen F, Drobne D. AP&T

Outcome of pregnancies in female IBD patients treated with vedolizumab (CONCEIVE):
Project leaders:
University Hospitals of Leuven (Belgium), the Erasmus MC (Rotterdam, The Netherlands), the Shaare Zedek Medical Center (Jerusalem, Israel)
Purpose and outcome: Very few data are available regarding pregnancy outcomes in female patients with IBD treated with vedolizumab. Expanding the existing study initiatives to a European level would certainly provide more data on the safety of vedolizumab in pregnancy and offspring. European research groups and individual IBD centers are invited to collaborate on this topic in a retrospective, multi-center cohort study.

Publications: Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Moens A, van der Woude CJ, Julsgaard M, Humblet E, Sheridan J, Baumgart DC, Gilletta De Saint-Joseph C, Nancey S, Rahier JF, Bossuyt P, Cremer A, Dewit S, Eriksson C, Hoentjen F, Krause T, Louis E, Macken E, Milenkovic Z, Nijs J, Posen A, Van Hootegem A, Van Moerkercke W, Vermeire S, Bar-Gil Shitrit A, Ferrante M. Aliment Pharmacol Ther. 2019 Nov 6. doi: 10.1111/apt.15539


Posted in Science


We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.